Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis have?
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis has 514 citations in the OpenAlex counts ScholarIQ stores.
When was Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis published?
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis has 2017 year in the ScholarIQ index.
What is the open-access status of Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis?
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis has bronze oa status in the ScholarIQ index.
What is the DOI of Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis?
The DOI for Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis is on the source record.
What is the PMID of Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis?
The PMID for Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis is on the source record.
What is the OpenAlex record for Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis?
The OpenAlex for Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis is on the source record.